US Drug Recall Register

FDA Drug Recalls

17,898 recalls, newest first

Class II · Moderate risk Ongoing

Airsupra

Reason Defective delivery system

AsttraZeneca Pharmaceuticals LP NDC 0310-9080-12 D-0444-2025
Class II · Moderate risk Ongoing

Celecoxib Capsules

Reason Presence of Foreign Tablets/Capsules: manufacturer recalled because one tadalafil 5mg tablet was found in 500 count bottle of Celecoxib 200 mg capsules

AvKARE NDC 50268-169-15 D-0460-2025
Class II · Moderate risk Ongoing

Esomeprazole Magnesium for Delayed-Release Oral Suspension

Reason Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation product during Related Compounds testing during long term stability.

Zydus Pharmaceuticals (USA) Inc NDC 68382-848-94 D-0443-2025
Class II · Moderate risk Ongoing

Esomeprazole Magnesium for Delayed-Release Oral Suspension

Reason Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation product during Related Compounds testing during long term stability.

Zydus Pharmaceuticals (USA) Inc NDC 68382-849-94 D-0442-2025
Class II · Moderate risk Ongoing

Chlorthalidone Tablets

Reason Failed Dissolution Specifications

AvKARE NDC 50268-167-15 D-0461-2025
Class II · Moderate risk Ongoing

Celecoxib Capsules

Reason Presence of Foreign Tablets/Capsules; customer complaint found one Tadalafil 5mg tablet inside a sealed 500-count bottle of Celecoxib 200mg capsule

Alembic Pharmaceuticals Limited NDC 62332-142-71 D-0459-2025
Class II · Moderate risk Ongoing

Bromfenac Ophthalmic Solution 0.09%

Reason Failed Impurities/Degradation Specifications

Alembic Pharmaceuticals Limited NDC 62332-508-17 D-0447-2025
Class I · High risk Ongoing

Endurance Boost With Horny Goat Weed

Reason Marketed without approved NDA/ANDA: The product has been found to be tainted with Sildenafil and Propoxyphenylsildenafil (a sildenafil analogue).

EnShiShiXiangNiShangMaoYouXianGongSi D-0453-2025
Class II · Moderate risk Ongoing

Testosterone Cypionate Injection

Reason Lack of Assurance of Sterility

Empower Clinic Services, LLC dba Empower Pharmacy D-0420-2025
Class II · Moderate risk Ongoing

TESTOSTERONE PELLET 200 mg BLUNT

Reason Presence of Particulate Matter: Glass particles were found in pellet vials.

Bso LLC D-0416-2025
Class II · Moderate risk Ongoing

TESTOSTERONE PELLET 200 mg

Reason Presence of Particulate Matter: Glass particles were found in pellet vials.

Bso LLC D-0415-2025
Class II · Moderate risk Ongoing

TESTOSTERONE PELLET 200 mg BLUNT

Reason Presence of Particulate Matter: Glass particles were found in pellet vials.

Bso LLC D-0414-2025
Class II · Moderate risk Ongoing

TESTOSTERONE PELLET 200 mg

Reason Presence of Particulate Matter: Glass particles were found in pellet vials.

Bso LLC D-0413-2025
Class II · Moderate risk Ongoing

TESTOSTERONE PELLET 100 mg

Reason Presence of Particulate Matter: Glass particles were found in pellet vials.

Bso LLC D-0412-2025
Class II · Moderate risk Ongoing

temper tamer

Reason CGMP Deviations

Siddha Flower Essences, LLC. NDC 69779-020-01 D-0410-2025
Class II · Moderate risk Ongoing

Infuvite Adult

Reason Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product.

Mckesson Medical-Surgical Inc. Corporate Office NDC 54643-5649-1 D-0401-2025
Class II · Moderate risk Ongoing

Medroxyprogesterone Acetate Injectable Suspension

Reason Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product.

Mckesson Medical-Surgical Inc. Corporate Office NDC 55150-0330-01 D-0400-2025
Class II · Moderate risk Terminated

Nature Mint

Reason CGMP Deviations

Kenil Healthcare Private Limited NDC 53247-131-05 D-0440-2025
Class II · Moderate risk Terminated

Nature Mint

Reason CGMP Deviations

Kenil Healthcare Private Limited NDC 53247-131-07 D-0437-2025
Class II · Moderate risk Terminated

Nature Mint

Reason CGMP Deviations

Kenil Healthcare Private Limited NDC 53247-131-02 D-0436-2025
Class II · Moderate risk Terminated

Nature Mint

Reason CGMP Deviations

Kenil Healthcare Private Limited NDC 53247-131-06 D-0435-2025